Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

Stephen A. Sherwin net worth and biography

Stephen Sherwin Biography and Net Worth

Director of Neurocrine Biosciences

Stephen A. Sherwin, M.D. has served on the Board of Directors since April 1999. Dr. Sherwin currently divides his time between advisory work in the life science industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco, and a volunteer Attending Physician in Hematology-Oncology at the Zuckerberg San Francisco General Hospital. Dr. Sherwin currently serves on the Board of Directors of Aduro Biotech, Biogen, Neon Therapeutics, and BioPlus. He is a Venture Partner with Third Rock Ventures and a member of the Scientific Steering Committee of the Parker Institute for Cancer Immunotherapy. Previously Dr. Sherwin was Chairman and Chief Executive Officer of Cell Genesys, a cancer immunotherapy company, from 1990 until the company’s merger in 2009 with BioSante Pharmaceuticals (now ANI Pharmaceuticals). He was also a Co-founder and Chairman of Abgenix, an antibody company that was acquired by Amgen in 2006, and Co-founder and Chairman of Ceregene, a gene therapy company which was acquired by Sangamo Biosciences in 2013. From 1983 to 1990, Dr. Sherwin held various positions in clinical research at Genentech, most recently that of Vice President. Prior to 1983, he was on the staff of the National Cancer Institute. In addition, Dr. Sherwin previously served on the Board of Directors of the Biotechnology Industry Organization from 2001 to 2014 and as its Chairman from 2009 to 2011, and was a member of the President’s Council of Advisors in Science and Technology (PCAST) Working Group on Drug Development from 2011 to 2013. Dr. Sherwin holds a B.A. in Biology, summa cum laude, from Yale University and an M.D. from Harvard Medical School, is board-certified in internal medicine and medical oncology, and is a fellow of the American College of Physicians.

What is Stephen A. Sherwin's net worth?: The estimated net worth of Stephen A. Sherwin is at least $3.51 million as of January 3rd, 2023. Dr. Sherwin owns 25,055 shares of Neurocrine Biosciences stock worth more than $3,509,955 as of April 24th. This net worth estimate does not reflect any other assets that Dr. Sherwin may own. Learn More about Stephen A. Sherwin's net worth.
How do I contact Stephen A. Sherwin?: The corporate mailing address for Dr. Sherwin and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected]. Learn More on Stephen A. Sherwin's contact information.
Has Stephen A. Sherwin been buying or selling shares of Neurocrine Biosciences?: Stephen A. Sherwin has not been actively trading shares of Neurocrine Biosciences during the last ninety days. Most recently, Stephen A. Sherwin sold 30,000 shares of the business's stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $118.86, for a transaction totalling $3,565,800.00. Following the completion of the sale, the director now directly owns 25,055 shares of the company's stock, valued at $2,978,037.30. Learn More on Stephen A. Sherwin's trading history.
Who are Neurocrine Biosciences' active insiders?: Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.
Are insiders buying or selling shares of Neurocrine Biosciences?: During the last year, insiders at the sold shares 46 times. They sold a total of 513,358 shares worth more than $66,594,857.00. The most recent insider tranaction occured on April, 15th when insider Eric Benevich sold 19,818 shares worth more than $2,642,928.48. Insiders at Neurocrine Biosciences own 4.4% of the company. Learn More about insider trades at Neurocrine Biosciences.
Information on this page was last updated on 4/15/2024.

Stephen A. Sherwin Insider Trading History at Neurocrine Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/3/2023	Sell	30,000	$118.86	$3,565,800.00	25,055
1/24/2022	Sell	15,000	$74.43	$1,116,450.00
4/28/2020	Sell	17,687	$99.39	$1,757,910.93	29,861
6/11/2018	Sell	10,000	$98.44	$984,400.00	47,548

Stephen A. Sherwin Buying and Selling Activity at Neurocrine Biosciences

Neurocrine Biosciences Company Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $140.09

$139.22

$145.00

50 Day Range

MA: $136.34

$130.40

$143.74

2 Week Range

Now: $140.09

$89.04

$148.37

Volume

1,607,701 shs

Average Volume

849,997 shs

Market Capitalization

$13.94 billion

P/E Ratio

57.89

Dividend Yield

N/A

Beta

0.25

Bitcoin Rockets To Record High But Buy THIS Instead

From Paradigm Press | Ad